Effect of brofaromine and pargyline on human plasma melatonin concentrations
Bieck, Peter R., Karl-Heinz Antonin, Richard Balon and Gregory Oxenkrug: Effect of brofaromine and pargyline on human plasma melatonin concentrations. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 1988, 12 : 93–101. 1. 1. Plasma melatonin was used to determine the influence of two monoamine oxi...
Gespeichert in:
| Veröffentlicht in: | Progress in neuro-psychopharmacology & biological psychiatry 1988, Vol.12 (1), p.93-101 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 101 |
|---|---|
| container_issue | 1 |
| container_start_page | 93 |
| container_title | Progress in neuro-psychopharmacology & biological psychiatry |
| container_volume | 12 |
| creator | Bieck, Peter R. Antonin, Karl-Heinz Balon, Richard Oxenkrug, Gregory |
| description | Bieck, Peter R., Karl-Heinz Antonin, Richard Balon and Gregory Oxenkrug: Effect of brofaromine and pargyline on human plasma melatonin concentrations. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 1988,
12
: 93–101.
1.
1. Plasma melatonin was used to determine the influence of two monoamine oxidase inhibitor drugs in 11 normal subjects.
2.
2. Acute oral administration of the selective reversible MAO-A inhibitor brofaromine but not of the — in low doses — selective MAO-B inhibitor pargyline increased daytime melatonin with large variations in onset, degree and duration.
3.
3. Further investigation of this selective action on melatonin might help to better understand the action of the therapeutically effective antidepressive therapy with selective MAO-A inhibitors. |
| doi_str_mv | 10.1016/0278-5846(88)90064-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78201987</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0278584688900644</els_id><sourcerecordid>78201987</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-f20853713a958ff77b96c24bd7a8ed20f0d5d08766dfd442a4a601052e09b9fe3</originalsourceid><addsrcrecordid>eNp9kE1r3DAQhkVJSLdp_0ELPpTQHpyOLFmSL4GwJGlgIZf0LMb6aBRsaSt5A_n3tbPLHnMaZuaZl-Eh5CuFSwpU_IJGqrpVXPxQ6mcHIHjNP5AVVfOYN1SckNUR-Ug-lfIMAJQBOyNnjAlGhViRzY33zkxV8lWfk8ecxhBdhdFWW8x_X4elS7F62o0Yq-2AZcRqdANOKYZYmRSNi1PGKaRYPpNTj0NxXw71nPy5vXlc_643D3f36-tNbZgSU-0bUC2TlGHXKu-l7DthGt5bicrZBjzY1oKSQlhvOW-QowAKbeOg6zvv2Dm52Oduc_q3c2XSYyjGDQNGl3ZFS9UA7ZScQb4HTU6lZOf1NocR86umoBeJejGkF0NaKf0mUfP57Nshf9ePzh6PDtbm_ffDHovBwWeMJpQjJmXbiXaJudpjbnbxElzWxQQ3C7Mhz861TeH9P_4DDiCNpw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78201987</pqid></control><display><type>article</type><title>Effect of brofaromine and pargyline on human plasma melatonin concentrations</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Bieck, Peter R. ; Antonin, Karl-Heinz ; Balon, Richard ; Oxenkrug, Gregory</creator><creatorcontrib>Bieck, Peter R. ; Antonin, Karl-Heinz ; Balon, Richard ; Oxenkrug, Gregory</creatorcontrib><description>Bieck, Peter R., Karl-Heinz Antonin, Richard Balon and Gregory Oxenkrug: Effect of brofaromine and pargyline on human plasma melatonin concentrations. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 1988,
12
: 93–101.
1.
1. Plasma melatonin was used to determine the influence of two monoamine oxidase inhibitor drugs in 11 normal subjects.
2.
2. Acute oral administration of the selective reversible MAO-A inhibitor brofaromine but not of the — in low doses — selective MAO-B inhibitor pargyline increased daytime melatonin with large variations in onset, degree and duration.
3.
3. Further investigation of this selective action on melatonin might help to better understand the action of the therapeutically effective antidepressive therapy with selective MAO-A inhibitors.</description><identifier>ISSN: 0278-5846</identifier><identifier>EISSN: 1878-4216</identifier><identifier>DOI: 10.1016/0278-5846(88)90064-4</identifier><identifier>PMID: 3363166</identifier><identifier>CODEN: PNPPD7</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>Administration, Oral ; Adult ; Biological and medical sciences ; brofaromine ; Circadian Rhythm - drug effects ; Dose-Response Relationship, Drug ; Humans ; MAO-A inhibition ; Medical sciences ; Melatonin - blood ; Monoamine Oxidase Inhibitors - pharmacology ; Neuropharmacology ; normal subjects ; pargyline ; Pargyline - pharmacology ; Pharmacology. Drug treatments ; Piperidines - pharmacology ; plasma melatonin ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology</subject><ispartof>Progress in neuro-psychopharmacology & biological psychiatry, 1988, Vol.12 (1), p.93-101</ispartof><rights>1988</rights><rights>1988 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-f20853713a958ff77b96c24bd7a8ed20f0d5d08766dfd442a4a601052e09b9fe3</citedby><cites>FETCH-LOGICAL-c386t-f20853713a958ff77b96c24bd7a8ed20f0d5d08766dfd442a4a601052e09b9fe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/0278584688900644$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,4010,27900,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7759654$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3363166$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bieck, Peter R.</creatorcontrib><creatorcontrib>Antonin, Karl-Heinz</creatorcontrib><creatorcontrib>Balon, Richard</creatorcontrib><creatorcontrib>Oxenkrug, Gregory</creatorcontrib><title>Effect of brofaromine and pargyline on human plasma melatonin concentrations</title><title>Progress in neuro-psychopharmacology & biological psychiatry</title><addtitle>Prog Neuropsychopharmacol Biol Psychiatry</addtitle><description>Bieck, Peter R., Karl-Heinz Antonin, Richard Balon and Gregory Oxenkrug: Effect of brofaromine and pargyline on human plasma melatonin concentrations. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 1988,
12
: 93–101.
1.
1. Plasma melatonin was used to determine the influence of two monoamine oxidase inhibitor drugs in 11 normal subjects.
2.
2. Acute oral administration of the selective reversible MAO-A inhibitor brofaromine but not of the — in low doses — selective MAO-B inhibitor pargyline increased daytime melatonin with large variations in onset, degree and duration.
3.
3. Further investigation of this selective action on melatonin might help to better understand the action of the therapeutically effective antidepressive therapy with selective MAO-A inhibitors.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>brofaromine</subject><subject>Circadian Rhythm - drug effects</subject><subject>Dose-Response Relationship, Drug</subject><subject>Humans</subject><subject>MAO-A inhibition</subject><subject>Medical sciences</subject><subject>Melatonin - blood</subject><subject>Monoamine Oxidase Inhibitors - pharmacology</subject><subject>Neuropharmacology</subject><subject>normal subjects</subject><subject>pargyline</subject><subject>Pargyline - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperidines - pharmacology</subject><subject>plasma melatonin</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><issn>0278-5846</issn><issn>1878-4216</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1988</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1r3DAQhkVJSLdp_0ELPpTQHpyOLFmSL4GwJGlgIZf0LMb6aBRsaSt5A_n3tbPLHnMaZuaZl-Eh5CuFSwpU_IJGqrpVXPxQ6mcHIHjNP5AVVfOYN1SckNUR-Ug-lfIMAJQBOyNnjAlGhViRzY33zkxV8lWfk8ecxhBdhdFWW8x_X4elS7F62o0Yq-2AZcRqdANOKYZYmRSNi1PGKaRYPpNTj0NxXw71nPy5vXlc_643D3f36-tNbZgSU-0bUC2TlGHXKu-l7DthGt5bicrZBjzY1oKSQlhvOW-QowAKbeOg6zvv2Dm52Oduc_q3c2XSYyjGDQNGl3ZFS9UA7ZScQb4HTU6lZOf1NocR86umoBeJejGkF0NaKf0mUfP57Nshf9ePzh6PDtbm_ffDHovBwWeMJpQjJmXbiXaJudpjbnbxElzWxQQ3C7Mhz861TeH9P_4DDiCNpw</recordid><startdate>1988</startdate><enddate>1988</enddate><creator>Bieck, Peter R.</creator><creator>Antonin, Karl-Heinz</creator><creator>Balon, Richard</creator><creator>Oxenkrug, Gregory</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1988</creationdate><title>Effect of brofaromine and pargyline on human plasma melatonin concentrations</title><author>Bieck, Peter R. ; Antonin, Karl-Heinz ; Balon, Richard ; Oxenkrug, Gregory</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-f20853713a958ff77b96c24bd7a8ed20f0d5d08766dfd442a4a601052e09b9fe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1988</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>brofaromine</topic><topic>Circadian Rhythm - drug effects</topic><topic>Dose-Response Relationship, Drug</topic><topic>Humans</topic><topic>MAO-A inhibition</topic><topic>Medical sciences</topic><topic>Melatonin - blood</topic><topic>Monoamine Oxidase Inhibitors - pharmacology</topic><topic>Neuropharmacology</topic><topic>normal subjects</topic><topic>pargyline</topic><topic>Pargyline - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperidines - pharmacology</topic><topic>plasma melatonin</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bieck, Peter R.</creatorcontrib><creatorcontrib>Antonin, Karl-Heinz</creatorcontrib><creatorcontrib>Balon, Richard</creatorcontrib><creatorcontrib>Oxenkrug, Gregory</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Progress in neuro-psychopharmacology & biological psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bieck, Peter R.</au><au>Antonin, Karl-Heinz</au><au>Balon, Richard</au><au>Oxenkrug, Gregory</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of brofaromine and pargyline on human plasma melatonin concentrations</atitle><jtitle>Progress in neuro-psychopharmacology & biological psychiatry</jtitle><addtitle>Prog Neuropsychopharmacol Biol Psychiatry</addtitle><date>1988</date><risdate>1988</risdate><volume>12</volume><issue>1</issue><spage>93</spage><epage>101</epage><pages>93-101</pages><issn>0278-5846</issn><eissn>1878-4216</eissn><coden>PNPPD7</coden><abstract>Bieck, Peter R., Karl-Heinz Antonin, Richard Balon and Gregory Oxenkrug: Effect of brofaromine and pargyline on human plasma melatonin concentrations. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 1988,
12
: 93–101.
1.
1. Plasma melatonin was used to determine the influence of two monoamine oxidase inhibitor drugs in 11 normal subjects.
2.
2. Acute oral administration of the selective reversible MAO-A inhibitor brofaromine but not of the — in low doses — selective MAO-B inhibitor pargyline increased daytime melatonin with large variations in onset, degree and duration.
3.
3. Further investigation of this selective action on melatonin might help to better understand the action of the therapeutically effective antidepressive therapy with selective MAO-A inhibitors.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>3363166</pmid><doi>10.1016/0278-5846(88)90064-4</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-5846 |
| ispartof | Progress in neuro-psychopharmacology & biological psychiatry, 1988, Vol.12 (1), p.93-101 |
| issn | 0278-5846 1878-4216 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78201987 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Administration, Oral Adult Biological and medical sciences brofaromine Circadian Rhythm - drug effects Dose-Response Relationship, Drug Humans MAO-A inhibition Medical sciences Melatonin - blood Monoamine Oxidase Inhibitors - pharmacology Neuropharmacology normal subjects pargyline Pargyline - pharmacology Pharmacology. Drug treatments Piperidines - pharmacology plasma melatonin Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopharmacology |
| title | Effect of brofaromine and pargyline on human plasma melatonin concentrations |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T07%3A35%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20brofaromine%20and%20pargyline%20on%20human%20plasma%20melatonin%20concentrations&rft.jtitle=Progress%20in%20neuro-psychopharmacology%20&%20biological%20psychiatry&rft.au=Bieck,%20Peter%20R.&rft.date=1988&rft.volume=12&rft.issue=1&rft.spage=93&rft.epage=101&rft.pages=93-101&rft.issn=0278-5846&rft.eissn=1878-4216&rft.coden=PNPPD7&rft_id=info:doi/10.1016/0278-5846(88)90064-4&rft_dat=%3Cproquest_cross%3E78201987%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78201987&rft_id=info:pmid/3363166&rft_els_id=0278584688900644&rfr_iscdi=true |